Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States

作者：Cosette M. Wheeler, Rachael Adcock, William C. Hunt, Michael J. Robertson, Norah Torrez‐Martinez, Ruth McDonald, Emily Merchasin, Steven Jenison, Debbie Saslow, Nancy E. Joste, Philip E. Castle, Jane J. Kim, Jack Cuzick, Nancy E. Joste, Walter Kinney, Cosette M. Wheeler, William C. Hunt, Michael Robertson, Ruth McDonald, Alan Waxman, Steven Jenison, Philip E Castle, Jean Howe, Debbie Saslow, Jane J Kim, Mark H Stoler, R. W. Perkins, J. Cuzick, Salina Torres, Giovanna Rossi, Kevin English · 发表于：JNCI Journal of the National Cancer Institute · 年份：2024 · DOI：10.1093/jnci/djae327 · 被引用次数：8 · 研究领域：Cervical Cancer and HPV Research、Head and Neck Cancer Studies、Reproductive tract infections research

BACKGROUND: Various studies have reported on the impact of human papillomavirus (HPV) vaccines. Here we present the largest population-based investigation of genotype-specific distributions over the decade following implementation of the quadrivalent HPV vaccine (HPV-6/11/16/18) in the United States. METHODS: Liquid-based cervical cytology samples from individuals aged 15-30 years undergoing cervical screening throughout New Mexico were tested by broad-spectrum HPV genotyping. Weighted relative differences in HPV type-specific prevalence and 95% confidence intervals (CIs) were calculated by comparing individuals screened between 2007 and 2009 (n = 95 915) with individuals screened between 2013 and 2016 (n = 103 371). Weighted logistic regression was used to estimate relative risk of type-specific HPV infections. Tests of significance were 2-sided. RESULTS: Genotype-specific prevalence fell with statistical signficance for HPV-16 (relative difference = ‒52.6%, 95% CI = ‒56.9 to ‒48.3), HPV-18 (relative difference = ‒62.1%, 95% CI = ‒68.5 to ‒55.8), HPV-31 (relative difference = ‒34.2%, 95% CI = ‒42.1 to ‒26.3), and HPV-33 (relative difference = ‒31.8%, 95% CI = ‒48.4 to ‒15.1). The relative difference increased for other carcinogenic HPV types by 19.5% (95% CI = 14.3 to 24.6) when excluding HPV-16/18. Large reductions in HPV-6/11 relative differences were observed, but overall, noncarcinogenic, nonvaccine types increased. Comparing female individuals born in 1996 with female i...